Kernal Bio is VC-backed biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted delivery and minimal off-target effects. Our in vivo CAR-T program (KR-402) program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming inside the body and resulting in B-cell depletion within a week.

With $80M funding secured to date, Kernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boasting three FDA-approved therapies and over 120 patents. Based in Boston, MA, we are backed by Lilly, NVIDIA, Hummingbird Ventures, Amgen Ventures, HBM, NASA, and ARPA-H.